4E Therapeutics acquired by Eli Lilly and Company
Eli Lilly and Company acquired 4E Therapeutics, a therapeutics brand.
Preliminary: The announcement date is not yet independently verified.
Transaction summary
- Target
- 4E Therapeutics
- Acquirer
- Eli Lilly and Company
- Seller
- -
- Announced
- 2026-06-16(unverified)
- Geography
- -
- Type
- Acquisition
- Deal type
- Control
- Stake acquired
- -
- First added
- 2026-07-13
- Latest update
- 2026-10-29
Value and multiples
100% enterprise value
Undisclosed
Value not disclosed
Basis: FundComb estimate
Reported price is assumed to be 100% EV unless stated otherwise. Partial-stake estimates are qualified in the basis notes.
EV / revenue
-
Period not stated
Basis: FundComb estimate
EV / EBITDA
-
EBITDA basis not stated
Basis: FundComb estimate
Basis
- Enterprise value is unavailable.
Source summary
4E Therapeutics Acquired by Lilly to Advance Non-Opioid Approach to Chronic Pain - PR Newswire
ConfirmedPR Newswire item reports that 4E Therapeutics was acquired by Lilly to advance a non-opioid approach to chronic pain.
Open sourceContinue your research
Related transaction comps
Kelonia Therapeutics acquired by Eli Lilly and Company
2026-04-20 · Confirmed
View transaction → Same buyer / investorAtaiBeckley acquired by Eli Lilly and Company
- · Confirmed
View transaction → BiotechEdgewise Therapeutics' Muscular Dystrophy Business acquired by Servier
2026-07-13 · Confirmed
View transaction → BiotechCelgene acquired by Bristol-Myers Squibb
- · Confirmed
View transaction →